Abstract: Objective To evaluate the impact of terbivudine （LdT） combined with adefovir dipivoxil （ADV） therapy on renal functions in patients with decompensated hepatitis B liver cirrhosis. Methods In this cohort study,76 patients with HBV-induced decompensated liver cirrhosis were divided into two groups,and 39 cases in observation group received combination of LdT and ADV,and 37 cases in control group received lamivudine（LAM） and ADV therapy. All the patients were followed-up for 52 weeks. The estimated glomerular filtration rate（eGFR） were calculated as reported in literature. Results At the end of 52th week,serum ALT, ALB and TBIL levels,Child-Pugh scores and HBV DNA negative rates in the two groups were significantly improved as compared with those before treatment （P<0.05） and no significant differences between the two groups （P>0.05）;the eGFR in observation group was（118.5±14.2） ml.min-1.1.73 m^-2,significantly higher than that in the control group[（94.2±18.5） ml·min^-1·1.73 m^-2,P<0.05],and serum creatinine level in observation group was （70.5±8.8） μmol/L,significantly lower than that in the control group[（109.1±15.8） μmol/L,P<0.05]. Conclusion The combination of LdT and ADV therapy in dealing with ADV-resistance has a good efficacy in patients with HBV-induced decompensated liver cirrhosis,which needs further observation.

Key words: Liver cirrhosis, Hepatitis B, Telbivudine, Lamivudine, Adefovir dipivoxil, Estimated glomerular filtration rate, Therapy